Business Description
Catalyst Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US14888U1016
Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 38.69 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 15.26 | |||||
| Beneish M-Score | 0.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 46.2 | |||||
| 3-Year EBITDA Growth Rate | 39.2 | |||||
| 3-Year EPS without NRI Growth Rate | -6.1 | |||||
| 3-Year FCF Growth Rate | 8.7 | |||||
| 3-Year Book Growth Rate | 30.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 16.39 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.67 | |||||
| 9-Day RSI | 38.89 | |||||
| 14-Day RSI | 43.41 | |||||
| 6-1 Month Momentum % | 30.56 | |||||
| 12-1 Month Momentum % | -0.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.88 | |||||
| Quick Ratio | 2.68 | |||||
| Cash Ratio | 1.81 | |||||
| Days Inventory | 73.84 | |||||
| Days Sales Outstanding | 34.5 | |||||
| Days Payable | 43.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | 0.02 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.95 | |||||
| Operating Margin % | 21.8 | |||||
| Net Margin % | 17.93 | |||||
| FCF Margin % | 15.28 | |||||
| ROE % | 20.45 | |||||
| ROA % | 16.92 | |||||
| ROIC % | 32.93 | |||||
| ROC (Joel Greenblatt) % | 894.1 | |||||
| ROCE % | 23.99 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.79 | |||||
| Forward PE Ratio | 10.37 | |||||
| PE Ratio without NRI | 24.79 | |||||
| Shiller PE Ratio | 110.37 | |||||
| Price-to-Owner-Earnings | 138.72 | |||||
| PS Ratio | 4.25 | |||||
| PB Ratio | 4.18 | |||||
| Price-to-Tangible-Book | 8.36 | |||||
| Price-to-Free-Cash-Flow | 28.85 | |||||
| Price-to-Operating-Cash-Flow | 11.73 | |||||
| EV-to-EBIT | 19.01 | |||||
| EV-to-Forward-EBIT | 8.85 | |||||
| EV-to-EBITDA | 13.79 | |||||
| EV-to-Revenue | 4.14 | |||||
| EV-to-Forward-Revenue | 3.56 | |||||
| EV-to-FCF | 26.68 | |||||
| Price-to-Projected-FCF | 2.3 | |||||
| Price-to-Graham-Number | 2.99 | |||||
| Price-to-Net-Current-Asset-Value | 11.81 | |||||
| Price-to-Net-Cash | 29.08 | |||||
| Earnings Yield (Greenblatt) % | 5.26 | |||||
| FCF Yield % | 3.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Catalyst Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 369.256 | ||
| EPS (TTM) (€) | 0.56 | ||
| Beta | 1.01 | ||
| Volatility % | 46.19 | ||
| 14-Day RSI | 43.41 | ||
| 14-Day ATR (€) | 0.296501 | ||
| 20-Day SMA (€) | 14.30125 | ||
| 12-1 Month Momentum % | -0.79 | ||
| 52-Week Range (€) | 10.43 - 16.18 | ||
| Shares Outstanding (Mil) | 118.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Catalyst Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Catalyst Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Catalyst Pharmaceuticals Inc Frequently Asked Questions
What is Catalyst Pharmaceuticals Inc(FRA:CN2)'s stock price today?
The current price of FRA:CN2 is €13.79. The 52 week high of FRA:CN2 is €16.18 and 52 week low is €10.43.
When is next earnings date of Catalyst Pharmaceuticals Inc(FRA:CN2)?
The next earnings date of Catalyst Pharmaceuticals Inc(FRA:CN2) is 2024-05-08.
Does Catalyst Pharmaceuticals Inc(FRA:CN2) pay dividends? If so, how much?
Catalyst Pharmaceuticals Inc(FRA:CN2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers